ACADIA Pharmaceuticals Inc.
ACAD
$16.12
-$0.50-3.01%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 957.80M | 929.24M | 890.53M | 813.81M | 726.44M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 957.80M | 929.24M | 890.53M | 813.81M | 726.44M |
| Cost of Revenue | 385.09M | 347.19M | 433.31M | 405.08M | 393.26M |
| Gross Profit | 572.71M | 582.05M | 457.22M | 408.73M | 333.18M |
| SG&A Expenses | 473.53M | 454.91M | 434.41M | 413.31M | 406.56M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 858.62M | 802.10M | 867.72M | 818.39M | 799.82M |
| Operating Income | 99.18M | 127.14M | 22.82M | -4.59M | -73.38M |
| Income Before Tax | 258.08M | 136.69M | 45.74M | 14.91M | -51.04M |
| Income Tax Expenses | 31.62M | 8.19M | 15.18M | 16.62M | 10.25M |
| Earnings from Continuing Operations | 226.45 | 128.51 | 30.57 | -1.71 | -61.29 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 226.45M | 128.51M | 30.57M | -1.71M | -61.29M |
| EBIT | 99.18M | 127.14M | 22.82M | -4.59M | -73.38M |
| EBITDA | 115.06M | 139.44M | 34.27M | 6.07M | -67.83M |
| EPS Basic | 1.36 | 0.78 | 0.18 | -0.01 | -0.38 |
| Normalized Basic EPS | 0.48 | 0.55 | 0.15 | 0.04 | -0.22 |
| EPS Diluted | 1.36 | 0.77 | 0.17 | -0.02 | -0.39 |
| Normalized Diluted EPS | 0.48 | 0.55 | 0.15 | 0.03 | -0.22 |
| Average Basic Shares Outstanding | 662.86M | 661.14M | 659.40M | 657.30M | 654.77M |
| Average Diluted Shares Outstanding | 665.67M | 665.49M | 663.54M | 662.41M | 658.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
